share_log

交银国际:重申康方生物“买入”评级 目标价70港元

Bocom Intl: Reaffirms buy rating on Akeso with a target price of HKD 70.

新浪港股 ·  Jul 4 23:34

BOCOM Intl. released a research report that reiterated a "buy" rating on Akeso (09926) with a target price of HKD 70. The company recently held an investor meeting and invited the lead researcher of the Phase III HARMONi-A trial (using ivosidenib to treat EGFR-TKI resistant NSCLC) to further interpret the results. Experts believe that the probability of achieving a significant OS advantage in the global HARMONi trial is higher and bullish on ivosidenib's success overseas. In addition, the safety superiority of HARMONi-A trial may be a key advantage.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment